HPRA
An tÚdarás Rialála Táirgí Sláinte
Health Products Regulatory Authority

Outcome of the Process - Public Consultation on proposed fees for Human Medicines, Compliance, Medical Devices and Veterinary Medicines for 2027

1 RESPONSE TO THE CONSULTATION

The HPRA received no responses on the Human Medicines, Compliance and Medical Devices fee consultation and one response on the Veterinary Medicines consultation. We believe that the reason that we received only one response reflects the HPRA's commitment to maintain fees for 2027 at the same level as previous years.

2 SUMMARY OF RESPONSES RECEIVED

There was one response received from a veterinary medicines industry representative group.

The veterinary medicines industry representative group welcomed the HPRA's proposal not to apply a general increase to veterinary medicinal product fees for 2027. However, the group noted that current fees remain high for certain procedures, particularly decentralised procedures where Ireland acts as the reference member state. In addition, a fee is charged for each additional target species in new applications which can result in a significant cumulative cost. The group also requested confirmation that the detailed fee structure and individual fee categories remain unchanged.

3 HPRA RESPONSE

The HPRA has reviewed and considered the response.

Regarding the concerns relating to the fees for decentralised procedures where Ireland acts as the reference member state, these fees will not be increasing in 2027 but will be reviewed further in 2028.

The fee charged for additional target species within an application is currently capped at three additional target species fees and no additional target species fee is charged for species categorised as 'minor'. However, the HPRA acknowledges the groups' concerns relating to these fees for certain application types and has therefore decided not to charge these fees for subsequent recognition procedures.

The HPRA can confirm that, apart from the one change proposed above, the detailed fee structure and all individual fee categories will remain unchanged for 2027. The fee structure is available on our website: Fees > Medicines for animal use.

4 CONCLUSION

The HPRA's primary objective is the protection of public health but in delivering this we are committed to providing a first class service to the industry we regulate. We will continue to review the cost base of the HPRA and related fees. As always, we commit to reviewing our fees annually to ensure that the fee levels are appropriate to the functions and costs of the HPRA.

Consequently, we propose to submit the current fee structure to the Minister for Health for approval.

HPRA
Finance, Corporate and Legal Department
17 November 2026